Legal & General Group Plc Increases Stock Position in Cencora, Inc. $COR

Legal & General Group Plc increased its position in Cencora, Inc. (NYSE:COR) by 6.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,441,755 shares of the company’s stock after acquiring an additional 85,963 shares during the period. Legal & General Group Plc owned about 0.74% of Cencora worth $450,592,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Vestcor Inc raised its position in Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after acquiring an additional 28 shares during the period. Cornerstone Wealth Group LLC increased its stake in shares of Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares in the last quarter. Security Financial Services INC. increased its stake in shares of Cencora by 2.6% in the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after purchasing an additional 33 shares in the last quarter. Hemington Wealth Management raised its holdings in Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after purchasing an additional 35 shares during the period. Finally, Quadcap Wealth Management LLC lifted its position in Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. Robert W. Baird set a $415.00 price target on Cencora in a report on Tuesday, January 13th. Wells Fargo & Company increased their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Barclays boosted their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Bank of America lowered their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $399.00.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is owned by insiders.

Cencora Price Performance

NYSE COR opened at $351.97 on Wednesday. Cencora, Inc. has a 12-month low of $251.94 and a 12-month high of $377.54. The firm’s fifty day simple moving average is $354.84 and its two-hundred day simple moving average is $337.51. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $68.47 billion, a P/E ratio of 42.30, a P/E/G ratio of 1.69 and a beta of 0.68.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.73 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.